US 12,404,269 B2
Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof
Rong Sheng, Hangzhou (CN); Jia Li, Shanghai (CN); Dongyan Gu, Hangzhou (CN); Yubo Zhou, Shanghai (CN); Jun Wei, Hangzhou (CN); Mengmeng Zhang, Shanghai (CN); Yongzhou Hu, Hangzhou (CN); Kaixiang Zhang, Shanghai (CN); Jieyu Liu, Shanghai (CN); and Weijuan Kan, Shanghai (CN)
Assigned to ZHEJIANG UNIVERSITY, Hangzhou (CN); and SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai (CN)
Filed by ZHEJIANG UNIVERSITY, Hangzhou (CN); and SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai (CN)
Filed on Jun. 25, 2021, as Appl. No. 17/358,002.
Application 17/358,002 is a continuation of application No. PCT/CN2019/122973, filed on Dec. 4, 2019.
Claims priority of application No. 201811593915.2 (CN), filed on Dec. 25, 2018.
Prior Publication US 2022/0017505 A1, Jan. 20, 2022
Int. Cl. C07D 413/14 (2006.01); C07D 239/95 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 473/00 (2006.01); C07D 491/056 (2006.01); C07D 491/107 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 239/95 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 473/00 (2013.01); C07D 491/056 (2013.01); C07D 491/107 (2013.01)] 8 Claims
 
1. An aminoquinazolinone or aminoisoquinolinone having the following Structural General Formulas a or b, or pharmaceutically acceptable salts, stereoisomers or solvates thereof:

OG Complex Work Unit Chemistry
wherein
(1) For Structural General Formula a:
X=N or CH;
R1 is selected from hydrogen, C1-6 alkyl, cycloalkyl, or fluoroalkyl,
R2 is selected from hydrogen, C1-12 alkyl, cycloalkyl, fluoroalkyl, —(CH2)nNR5R6, —(CH2)n—CONR5R6, —(CH2)n—SO2NR5R6, or —(CH2)nOR5, wherein n is an integer selected from 1 to 8, R5 and R6 are independent of each other, may be the same or different, and are selected from hydrogen, C1-4 alkyl, or C1-4 cycloalkyl, or NR5R6 is a 4-8 membered cyclic amine, including but not limited to morpholine, piperazine, pyrrolidine, piperidine, or a cyclic amine substituted with R7 which is selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic chain hydrocarbon group, C3-8 cycloalkyl, C3-8 unsaturated alicyclic group, C3-8 saturated aliphatic heterocyclic group, halogen, amino, or cyano;
R3 is selected from C1-6 alkyl, cycloalkyl, or fluoroalkyl;
Ar is an aromatic heterocyclic ring, including but not limited to benzene ring, furan ring, thiophene ring, pyrrole ring, thiazole ring, pyrazole ring, oxazole ring, pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, purine ring, azapurine ring, azaindole ring, indole ring, quinoline ring, quinazoline ring, quinoxaline ring, or indazole ring;
R8 is selected from hydrogen, halogen, cyano, hydroxyl, C1-6 alkoxy, amino, C1-6 alkylamino, C1-6 dialkylamino, C1-6 alkyl, C2-6-unsaturated fat chain hydrocarbon group, C3-8 cycloalkyl, C3-8 unsaturated alicyclic group, C3-8 saturated aliphatic heterocyclic group, or C1-6 haloalkyl; and
(2) For Structural General Formula b:
The two adjacent oxygen atoms on the benzene ring of the quinazoline or quinoline are connected by different chains to form a 5-21 membered ring, and the chain contains 2-7 oxygen atoms; the rest of the structure has the same definition as the Structural General Formula a.